Bone marrow grafting and cellular therapies for leukemia and lymphoma
Official title: Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
Funded at Stanford University · NIH-11400072 · Data updated 2026-11-12
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 1, 1997 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,936,016 |
| NIH project number | 5P01CA049605-35 |
| Project ID | NIH-11400072 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with hematologic malignancies who may be candidates for hematopoietic cell transplantation or cellular therapies.
✕Less likely to help
Patients who are not eligible for transplantation or enrolled cellular therapies may not benefit.
What this research studies
This initiative focuses on understanding how transplantation works at the cellular level and developing advanced cell therapies, including iNKT cells, CAR T cells, regulatory T cells, and targeted antibody approaches. The researchers will use animal models, detailed molecular analyses, innovative imaging, and translational clinical trials to reduce risks such as graft-versus-host disease and relapse. The project is organized into four interactive components backed by supportive cores for administration, stats, and data management. The goal is to create more reliable, safer, and effective transplantation-based treatments for patients with hematologic cancers.
Why it matters
Potential benefit: If successful, patients could have safer transplant options with lower relapse rates and better control of disease using advanced cellular therapies.
How similar studies have gone: Previous work has shown promise in cellular therapies and GVHD prevention, with ongoing development of CAR T and iNKT cell strategies.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Negrin, Robert S — Stanford University
- Study coordinator: Negrin, Robert S
Related research
Other NIH-funded projects on the same topics.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
Understanding EP300 deficiency in ATLL in adults
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Improving bone marrow transplants and cell therapies for leukemia and lymphoma
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
-
Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
-
Understanding the causes of Adult T-cell leukemia/lymphoma
This study is looking at Adult T-cell leukemia/lymphoma, a tough cancer that often hits young adults, especially veterans, to find out why some patients don’t respond well to treatment and how we can make those treatments better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.